Air Canada (TSX:AC) Stock: You Want To Hear the Good News or the Bad News?

Air Canada (TSX:AC) stock is riding on the news more than the fundamentals. There are good news and bad news for AC investors in 2021. 

| More on:
An airplane on a runway

Image source: Getty Images.

Air Canada (TSX:AC) stock has been in the headlines throughout the year. Sometimes it was good news and sometimes bad news. It was this news on which traders made money as the stock moved between the $15-$20 price range. In November, the COVID-19 vaccine upped the game, and AC stock reached $27.5. But it dropped to $22 in December, as the second wave of the mutant coronavirus once again started the lockdown trend. The airline is at crossroads. AC stock could rise to $30 or fall to $20 on good and bad news.

The good news for Air Canada 

First the good news, the vaccine is out. The United States has approved the vaccines from Moderna and Pfizer, and both of them have arrived in Canada. The Justin Trudeau government hopes to make the vaccine available to anyone who wants it by September when the government’s recovery benefits end. If the vaccine succeeds in reducing virus spread and easing travel restrictions, AC will benefit from the pent up demand for leisure travel.

The second good news is that the Canadian government is considering an airline-specific bailout, and AC will be the key beneficiary. If AC gets a favourable bailout, its interest rate burden from mounting debt will ease, and it can return to profits faster.

In the meantime, AC is closing more routes, raising equity capital, and accelerating its plans to start a dedicated air cargo business. AC’s cargo business is at an early stage. If the management can earn money by putting the idle Boeing 737 Max to use as freighters, its revenue could surge.

The above news could send AC stock to $30 in 2021.

The bad news for Air Canada 

But every yang has a yin. All the above good news is built on hopes. They could backfire and instead of pushing AC to $30, pull it down to $20.

The first good news was a vaccine. But it is difficult to say how effective it is? The United Kingdom is seeing some alternate effects of the Pfizer vaccine. The government has asked people with allergies to not take the vaccine. Moreover, the country saw a mutation of the virus, and it is not clear if the vaccine will work on the mutant virus or not. If people are not willing to take the vaccine, the rollout will become even more challenging.

All of these hurdles in the vaccine rollout have extended travel restrictions till January 21, 2021. These restrictions will be extended further until the government feels it is safe to open the borders.

The next good news of airline-specific bailout has become more of a battlefield. The government is putting conditions like canceled ticket refunds and restarting services on suspended routes without telling the bailout amount. AC CEO will accept these terms only when bailout money and terms are satisfactory.

The third good news of AC cargo business has started with a warning. After lying idle since March 2019, when the Boeing 737 Max aircraft took to the skies as a freighter, an engine failure forced the plane to land.

Some unexpected events could pull Air Canada stock to $15 

There is more bad news than good news for AC. Fuel accounts for 20% of an airline’s operating expense. AC managed to control its losses in the third quarter to $609 million due to low oil prices. But the oil price is surging which could increase AC’s losses in the fourth quarter.

In such challenging times, AC’s CEO Calin Rovinescu is retiring in February 2021. It is not clear how the management change will impact the airline. It could be good or bad. There will be a lot of turbulence in AC stock in February 2021. Higher fourth-quarter loss, continued travel restrictions, and management change could pull the stock down to $15.

Playing on the seesaw stock price movement 

Now that you know what is good and bad for AC, you can buy the stock near the $20 price when the sentiment is bearish and sell the stock at the $27 price when things are rosy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Puja Tayal has no position in any of the stocks mentioned.

More on Coronavirus

movies, theatre, popcorn

How Much is $1000 in AMC Stock Worth 1 Year Later?

AMC was once a stellar growth stock, but it’s taken a serious hit. So how much is $1,000 worth a…

Read more »

Airport and plane

Air Canada Stock Could Keep Trading Weak as Challenges Mount

Should you buy AC stock?

Read more »

Arrow descending on a graph

Why Cineplex (TSX:CGX) Stock Fell to 2-Year Lows Last Week

Is the recent correction in CGX stock really an opportunity?

Read more »

Business success with growing, rising charts and businessman in background

1 Growth Stock Every Canadian Investor Should Consider Right Now

This growth stock saw shares pop 10% on June 20, as one analyst stated there is a significant opportunity to…

Read more »

Aircraft wing plane

Bombardier Stock Merge: What it Means for Investors

Bombardier (TSX:BBD.B) stock went through a reverse stock split on June 13, turning 25 shares into one in one swift…

Read more »

Aircraft wing plane

Air Canada (TSX:AC) Stock: Ready to Take Off?

While Air Canada is handling what it can control really well, there are many worsening macro headwinds that will likely…

Read more »

rail train

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Biotech stocks

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »